List of Zometa drug patents

Zometa is owned by Novartis.

Zometa contains Zoledronic Acid.

Zometa has a total of 3 drug patents out of which 0 drug patents have expired.

Zometa was authorised for market use on 20 August, 2001.

Zometa is available in injectable;intravenous dosage forms.

Zometa can be used as multiple myeloma; bone metastases; hypercalcemia of malignancy.

The generics of Zometa are possible to be released after 05 February, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324189 NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
May, 2025

(2 years from now)

US8324189

(Pediatric)

NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Nov, 2025

(2 years from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates
Feb, 2028

(5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 20 August, 2001

Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ZOMETA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in